# BNC KOREA

> BNC KOREA is a VC fund in Seoul backing Biotechnology and Pharmaceutical. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 3
- Last investment: May 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bnc-korea-inc
- Website: http://www.bnckorea.co.kr
- Facebook: https://www.facebook.com/www.bnckorea.co.kr

BNC Korea is a research laboratory that creates strategic application products for biomarkets.

## Contacts

5 contacts available for BNC KOREA. Shizune tracks 1 team members at BNC KOREA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bnc-korea?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Pharmaceutical | 2 | 67% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series C | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Choi Wan-kyu | CEO | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GeneMedicine | GeneMedicine(GM) is a clinical stage biopharmaceutical company that focuses on developing next-generation viral immunotherapies, aiming to transform the therapeutic outcomes for cancer patients. Using their proprietary adenovirus platform, GM is developing several pipeline products that can be intratumorally and intravenously administered toselectively attack and eradicate tumor cells as well as potently stimulating multiple arms of antitumor immune response. GM’s viral immunotherapy has proven effective as both a standalone therapy and in combination with current standard of care, including immune checkpoint inhibitors (ICI). |  | Series C | May 20, 2025 |  |
| ProAbTech | ProAbTech develops biotechnology solutions focused on site-specific bioconjugation technology for therapeutic proteins and antibodies. Its platform enhances the precision, stability, and functionality of biologic drugs. The company works on advanced drug development solutions aimed at improving targeted therapies and supporting innovation inprotein-based pharmaceuticals and medical research applications. | $2.2M | Series B | Apr 03, 2024 |  |
| Mitoimmune Therapeutics | Mito Immune Therapeutics is a drug research and development biotech company. | $3.9M | Series B | Sep 21, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [BMI KOREA](https://shizune.co/investors/profile/bmi-korea) — VC Fund, 1 deal together
- [Hanwha Investment & Securities](https://shizune.co/investors/profile/hanwha-investment-securities) — VC Fund, 1 deal together
- [K Ground Ventures](https://shizune.co/investors/profile/k-ground-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does BNC KOREA invest in?

BNC KOREA invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BNC KOREA?

Public channels for BNC KOREA include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BNC KOREA?

The team at BNC KOREA includes Choi Wan-kyu (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co